Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
La Verde N, Damia G, Garrone O, Santini D, Fabi A, Ciccarese M, Generali DG, Nunzi M, Poletto E, Ferraris E, Cretella E, Scandurra G, Meattini I, Bertolini AS, Cavanna L, Collovà E, Romagnoli E, Rulli E, Legramandi L, Guffanti F, Bramati A, Moretti A, Cassano A, Vici P, Torri V, Farina G; PAINTER investigators. La Verde N, et al. Among authors: collova e. Breast Cancer Res. 2022 Oct 28;24(1):71. doi: 10.1186/s13058-022-01560-w. Breast Cancer Res. 2022. PMID: 36307826 Free PMC article. Clinical Trial.
Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor.
Ferrari S, Rovati B, Porta C, Alessandrino PE, Bertolini A, Collovà E, Riccardi A, Danova M. Ferrari S, et al. Among authors: collova e. Cancer Immunol Immunother. 2003 Jun;52(6):359-66. doi: 10.1007/s00262-002-0365-4. Epub 2003 Mar 27. Cancer Immunol Immunother. 2003. PMID: 12664135 Free PMC article.
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R. Garassino MC, et al. Among authors: collova e. Lung Cancer. 2011 Jun;72(3):378-83. doi: 10.1016/j.lungcan.2010.09.009. Epub 2010 Oct 15. Lung Cancer. 2011. PMID: 20950888 Clinical Trial.
Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis.
Collovà E, Ferzi A, Scandurra G, Aurilio G, Torri V, Porcu L, Sanò MV, Taibi E, Foglietta J, Generali D, Andreis D, Dazzani MC, Bramati A, Marcon I, Atzori F, Cinieri S, Tondulli L, Grasso D, Nolè F, Petrella MC, Gori S, La Verde N. Collovà E, et al. Tumori. 2014 Jul-Aug;100(4):426-31. doi: 10.1700/1636.17902. Tumori. 2014. PMID: 25296592
Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology.
Aurilio G, Gori S, Nolè F, Pruneri G, Coati F, Torri V, Lunardi G, Atzori F, La Verde N, Banna GL, Rossi A, Del Mastro L, Di Fabio F, Marcon I, Gebbia V, Loupakis F, Orlando L, Ciuffreda L, Amadio P, Luppi G, Redana S, Filippelli G, Gentile A, Collovà E. Aurilio G, et al. Among authors: collova e. Tumori. 2016 Jan-Feb;102(1):108-13. doi: 10.5301/tj.5000383. Epub 2015 Jul 2. Tumori. 2016. PMID: 26166216
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.
Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G. Santini D, et al. Among authors: collova e. Sci Rep. 2015 Dec 22;5:18670. doi: 10.1038/srep18670. Sci Rep. 2015. PMID: 26690845 Free PMC article.
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study.
Gagno S, D'Andrea MR, Mansutti M, Zanusso C, Puglisi F, Dreussi E, Montico M, Biason P, Cecchin E, Iacono D, Russo S, Cinausero M, Saracchini S, Gasparini G, Sartori D, Bari M, Collovà E, Meo R, Merkabaoui G, Spagnoletti I, Pellegrino A, Gianni L, Sandri P, Cretella E, Vattemi E, Rocca A, Serra P, Fabbri MA, Benedetti G, Foghini L, Medici M, Basso U, Amoroso V, Riccardi F, Baldelli AM, Clerico M, Bonura S, Saggia C, Innocenti F, Toffoli G. Gagno S, et al. Among authors: collova e. Clin Breast Cancer. 2019 Apr;19(2):137-145.e4. doi: 10.1016/j.clbc.2018.11.009. Epub 2018 Nov 24. Clin Breast Cancer. 2019. PMID: 30584056 Free article.
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
Caputo R, Cazzaniga ME, Sbrana A, Torrisi R, Paris I, Giordano M, Montesarchio V, Guarneri V, Amaducci L, Bilancia D, Cilenti G, Fabi A, Collovà E, Schirone A, Bonizzoni E, Celio L, De Placido S, De Laurentiis M. Caputo R, et al. Among authors: collova e. BMC Cancer. 2020 Mar 19;20(1):232. doi: 10.1186/s12885-020-6707-9. BMC Cancer. 2020. PMID: 32188417 Free PMC article. Clinical Trial.
31 results